Analyst Consensus ?
ConsensusBuy29 ratings
Bullish1862.1%
Neutral1034.5%
Bearish13.4%
Willis Towers Watson Public Limited Company · WTW · FY2025 Q3 · Calendar Q4 2025
WTW: 5% Organic Growth, Margin Expansion and AI Investment
The supplied analysis supports a constructive but conditional view: resilient demand in health benefits and specialty insurance, combined with automation and digital platforms, can support growth and margin expansion. The thesis remains dependent on recurring revenue quality, insurance pricing, geographic trends and cash generation.
Reported Before market openNASDAQFinancial Services
$26.80B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$3.07
Consensus $3.05
EPS surprise
+0.7%
Reported versus consensus
Reported revenue
$2.29B
Consensus $2.27B
Revenue surprise
+0.6%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-0.2%
Event window
SPY move
-1.1%
Same window
Abnormal move
+0.9%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
+1.3%
Up to 20 sessions
WTWSPY benchmark
Ask FN2 about WTW FY2025 Q3
Transcript, numbers and history already loaded
Why did WTW fall 0.2% after beating EPS estimates in FY2025 Q3?What changed in WTW's guidance and outlook in FY2025 Q3?Give me the bull and bear case for WTW after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the supplied prior-quarter analysis, the current analysis puts greater emphasis on Radar 5, Gemini and AI-driven analytics as growth engines, reports stronger quarterly margin expansion, and adds explicit concerns about rate softness, recurring versus one-off specialty revenue and the $1.5 billion buyback target.
Guidance delta
Management maintained its guidance for mid-single-digit organic growth and continued margin expansion; the supplied analysis also says the $1.5 billion 2025 share-repurchase target was reaffirmed.
Key takeaways
- The supplied analysis describes 5% organic growth and 230 basis points of adjusted operating-margin expansion to 20.4%.
- Health, Wealth & Career and Risk & Broking both contributed to growth, while Risk & Broking faced pricing pressure.
- Radar 5, Gemini and AI-driven analytics were highlighted as core technology and growth initiatives.
- Management continued to emphasize talent, automation, specialization and disciplined capital allocation.
- The divestiture of TRANZACT was described as creating an earnings headwind and a cash-flow tailwind.
Management priorities
- Roll out additional AI-driven analytics tools across segments
- Expand the Gemini digital placement platform into new markets
- Pursue margin improvement through automation and right-shoring
- Maintain disciplined capital allocation across buybacks, selective M&A and talent investment
- Use EU pay-transparency work to deepen advisory services
Follow WTW with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$288.61Current
$247Low
$342.31Average
$405High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Outperform | Outperform | Maintain | Sep 16, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 20, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Aug 19, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Aug 4, 2026 |
| UBS | Buy | Buy | Maintain | Aug 3, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Aug 3, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Aug 3, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jul 31, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 7, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 1, 2026 |
| BMO Capital | Outperform | Market Perform | Upgrade | May 1, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 14, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Sep 22, 2025 |
| Jefferies | Buy | Buy | Maintain | Apr 11, 2025 |
| Roth MKM | Buy | Buy | Maintain | Jul 26, 2024 |
| Stifel | Hold | Hold | Maintain | Feb 7, 2024 |
| Baird | Outperform | Outperform | Maintain | May 1, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Dec 15, 2022 |
| MKM Partners | Buy | Buy | Maintain | Dec 5, 2022 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Oct 19, 2021 |
| Deutsche Bank | Hold | Hold | Maintain | May 3, 2021 |
| CFRA | Buy | Hold | Upgrade | Mar 8, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jul 10, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Jan 15, 2018 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Jun 23, 2016 |
| JP Morgan | Underweight | Underweight | Maintain | Feb 9, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $288.61. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Yaron Kinar | $380 | $321.97 | +31.7% | Sep 16, 2026 |
| Morgan Stanley | Analyst unavailable | $350 | $327.9 | +21.3% | Aug 19, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $380 | $341.09 | +31.7% | Aug 3, 2026 |
| UBS | Brian Meredith | $405 | $341.04 | +40.3% | Aug 3, 2026 |
| Morgan Stanley | Bob Huang | $315 | $341.39 | +9.1% | Aug 3, 2026 |
| Robert W. Baird | Mark Marcon | $385 | $336.05 | +33.4% | Jul 31, 2026 |
| Mizuho Securities | Yaron Kinar | $406 | $336.05 | +40.7% | Jul 31, 2026 |
| Atlantic Equities | Analyst unavailable | $360 | $287.3 | +24.7% | Jul 15, 2026 |
| Piper Sandler | Paul Newsome | $317 | $288.74 | +9.8% | Jul 15, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $344 | $292.58 | +19.2% | Jul 9, 2026 |
| Mizuho Securities | Analyst unavailable | $361 | $292.58 | +25.1% | Jul 9, 2026 |
| UBS | Analyst unavailable | $382 | $291.47 | +32.4% | Jul 8, 2026 |
| UBS | Analyst unavailable | $374 | $258.12 | +29.6% | Jun 9, 2026 |
| Raymond James | Analyst unavailable | $340 | $261.92 | +17.8% | May 6, 2026 |
| Mizuho Securities | Analyst unavailable | $338 | $259.37 | +17.1% | May 5, 2026 |
| Morgan Stanley | Analyst unavailable | $275 | $259 | -4.7% | May 1, 2026 |
| Robert W. Baird | Mark Marcon | $335 | $260.24 | +16.1% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $360 | $263.78 | +24.7% | May 1, 2026 |
| Piper Sandler | Paul Newsome | $283 | $256.2 | -1.9% | May 1, 2026 |
| BMO Capital | Analyst unavailable | $300 | $256.2 | +3.9% | May 1, 2026 |
| Truist Financial | Mark Hughes | $320 | $256.33 | +10.9% | Apr 30, 2026 |
| Mizuho Securities | Analyst unavailable | $353 | $285.58 | +22.3% | Apr 13, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $354 | $287.86 | +22.7% | Apr 9, 2026 |
| Piper Sandler | Paul Newsome | $341 | $301.81 | +18.2% | Feb 23, 2026 |
| UBS | Analyst unavailable | $409 | $319.38 | +41.7% | Feb 9, 2026 |
| Truist Financial | Analyst unavailable | $400 | $338.86 | +38.6% | Feb 4, 2026 |
| Mizuho Securities | Analyst unavailable | $392 | $335.1 | +35.8% | Feb 4, 2026 |
| Wells Fargo | Analyst unavailable | $379 | $335.1 | +31.3% | Feb 4, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $345 | $329.28 | +19.5% | Jan 14, 2026 |
| Mizuho Securities | Analyst unavailable | $388 | $327.42 | +34.4% | Jan 14, 2026 |
| Wells Fargo | Elyse Greenspan | $366 | $329.45 | +26.8% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $318 | $331.38 | +10.2% | Jan 8, 2026 |
| Goldman Sachs | Analyst unavailable | $375 | $331.38 | +29.9% | Jan 7, 2026 |
| Evercore ISI | Analyst unavailable | $383 | $333.38 | +32.7% | Jan 7, 2026 |
| Mizuho Securities | Yaron Kinar | $386 | $330.76 | +33.7% | Dec 15, 2025 |
| Wells Fargo | Analyst unavailable | $356 | $325.52 | +23.3% | Dec 12, 2025 |
| Barclays | Alex Scott | $303 | $317.26 | +5.0% | Nov 20, 2025 |
| UBS | Brian Meredith | $398 | $348.68 | +37.9% | Oct 8, 2025 |
| Barclays | Alex Scott | $341 | $349.93 | +18.2% | Oct 8, 2025 |
| Piper Sandler | Analyst unavailable | $387 | $347.07 | +34.1% | Oct 6, 2025 |
| Evercore ISI | Analyst unavailable | $387 | $343.95 | +34.1% | Oct 1, 2025 |
| Wells Fargo | Analyst unavailable | $377 | $342.2 | +30.6% | Sep 30, 2025 |
| Morgan Stanley | Bob Huang | $345 | $329.31 | +19.5% | Aug 18, 2025 |
| Jefferies | Yaron Kinar | $382 | $311 | +32.4% | Dec 20, 2024 |
| Raymond James | Greg Peters | $400 | $331.79 | +38.6% | Dec 5, 2024 |
| Barclays | Alex Scott | $278 | $294.38 | -3.7% | Sep 4, 2024 |
| Wells Fargo | Elyse Greenspan | $321 | $281.52 | +11.2% | Jul 26, 2024 |
| Truist Financial | Mark Hughes | $335 | $280.81 | +16.1% | Jul 26, 2024 |
| CFRA | Catherine Seifert | $315 | $280.96 | +9.1% | Jul 26, 2024 |
| Evercore ISI | David Motemaden | $319 | $277.6 | +10.5% | Jul 25, 2024 |
| BMO Capital | Michael Zaremski | $298 | $272.2 | +3.3% | Feb 12, 2024 |
| Wells Fargo | Jared Shaw | $288 | $247.07 | -0.2% | Jan 11, 2024 |
| BMO Capital | Michael Zaremski | $205 | $203.44 | -29.0% | Aug 8, 2023 |
| Goldman Sachs | Robert Cox | $290 | $237.74 | +0.5% | Feb 27, 2023 |
| Goldman Sachs | Analyst unavailable | $271 | $256.13 | -6.1% | Jan 9, 2023 |
| Raymond James | Analyst unavailable | $280 | $245.24 | -3.0% | Dec 29, 2022 |
| Credit Suisse | Analyst unavailable | $302 | $243.42 | +4.6% | Dec 15, 2022 |
| Citigroup | Analyst unavailable | $247 | $245.63 | -14.4% | Dec 15, 2022 |
| MKM Partners | Analyst unavailable | $285 | $248 | -1.3% | Dec 5, 2022 |
| Morgan Stanley | Analyst unavailable | $240 | $236.06 | -16.8% | Nov 22, 2022 |
| Goldman Sachs | Robert Cox | $227 | $194.85 | -21.3% | Jul 15, 2022 |
Track every rating change on WTW the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationWillis Towers Watson Public Limited Company (WTW) functions as a global provider of comprehensive consulting, brokerage, and solutions services. Its operations are structured across two primary divisions: Health, Wealth and Career, and Risk and Broking. Within the Health, Wealth and Career segment, WTW furnishes actuarial guidance, plan development, and administrative assistance for conventional pension and retirement savings schemes. It also delivers consulting, brokerage, and management services for health and group employee benefit programs, along with outsourced benefits administration. Furthermore, the company offers strategic counsel, analytical data, specialized software, and various products designed to help clients effectively manage their overall compensation and human capital challenges. The Risk and Broking division extends expertise in risk management, insurance placement, and advisory services, covering sectors such as property and casualty, aerospace, construction, and marine.…
Historical context
All WTW earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FDS FactSet Research Systems Inc. | FY2026 Q4 · Calendar Q3 2026 | +3.9% | +3.8% | FactSet reports record FY26 results as AI and MCP adoption accelerate |
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the WTW recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
- Polygon adjusted daily market bars · 2026-10-03T05:06:05.447292+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-03T05:06:05.444089+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-03. For educational purposes only; not investment advice.